Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Mesothelin-targeted CAR-T Cells as a Neo-adjuvant Treatment in Patients With Resectable Pancreatic Cancers: a Feasibility Study

NCT06054308 is registered in ClinicalTrials.gov with Chinese University of Hong Kong as lead sponsor.

NCT NCT06054308
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06054308 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Mesothelin-targeted CAR-T Cells as a Neo-adjuvant Treatment in Patients With Resectable Pancreatic Cancers: a Feasibility Study
Lead sponsor
Chinese University of Hong Kong
Phase
Not applicable
Overall status
Withdrawn
Start date
February 2, 2024
Completion date
August 2, 2026
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer